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ABSTRACT
Scholars and policymakers agree that early-stage venture capital
is the most important element of innovation pipeline in the
health care industry. However, securing the financing at the very
beginning of innovation pathway in health care is challenging
and relies on an in-depth understanding of investment strategies
implemented by venture capitalists. In turn, this requires us to
take a broader look at global trends in early-stage venture capital
funding of health care oriented life-science projects. Referred to
the above, this article aims to provide the outlook for early-stage
venture capital investment in Europe and provide its benchmark-
ing performance analysis. Using data on early-stage venture
investments in health care-related life-science projects, we present
its long-term dynamics and analyse current trends. Additionally,
we check whether investment decisions are motivated by the
short-term return opportunities or they are made as a part of
long-term strategy. We find that Europe, with uneven and volatile
financings, is still lagging behind the investment levels of the U.S.
Our findings also support the cautionary behaviour of investors
and their awareness towards the highly volatile nature of short-
term returns.
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For many years health care has been the largest sector in many developed and devel-
oping economies. It is also one of the most rapidly changing, being the arena for dra-
matic achievements and failures, a continuous battlefield for resources in times of
disruptive technology. It is precisely this technological progress that is the key factor
that not only transforms and redefines the practice of medicine, but profoundly rede-
signs its economic and social dimensions. Indeed, many new medicines, devices or
medical services seem to be extremely promising in eradicating illnesses and/or raising
quality of life for sick patients, but their potential is frequently dimmed by insufficient
financial resources of health providers, leading frequently to systemic inefficiencies.
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There are still important obstacles on the road towards a healthier population. For
instance, it might be the case that a new molecule, after being discovered and success-
fully tested in clinical trials, becomes available on the market, but the manufacturer’s
asking price is beyond the reach of patients or the reimbursement capacity of health
care system payer (DiMasi, Feldman, Seckler, & Wilson, 2010). As a result, it is
impossible for patients to get access to the treatment. This situation is also extremely
harmful for a drug developer, who finds himself in a difficult situation of not being
able to cover his R&D expenses and, eventually, make him slow down or stop innov-
ation efforts altogether.
This situation is unfortunately a very frequent one. The good news is, however,
that the solution to the problem lies in creating the highest value from available
resources, which consists on raising health outcomes while decreasing costs of care.
This is precisely what both scholars and policymakers agree on: raising economic-
ally sustainable health outcomes is only possible when there is sufficient innovation.
Clearly, fuelling the innovation pipeline has become a priority in many countries. It
must be remembered, however, that innovation processes in health care industry
require substantial investments in terms of resources and time.1 Moreover, transform-
ing knowledge into innovative medical devices, services, or identifying the promising
active molecule of a future drug, is a risky endeavour, since the entire innovation
process in health care displays high levels of uncertainty.2 Therefore, maintaining the
levels of innovation supposed to improve health outcomes remains challenging and
somehow fragile.
For many years now, the global health care industry has been confronted to
some important adverse phenomena that might potentially slower its innovation
dynamics. First, spending on health-related R&D in Europe, both public and pri-
vate, is lagging behind the financing levels of the U.S. (Politico, 2015). Second, the
pharmaceutical sector, which has always been the leader and main development
driver of the health care industry, has witnessed the decline in economic returns
from new drugs (Berndt, Nass, Kleinrock, and Aitken, 2015). Finally, for the last
five years, there has been a pronounced decline in the amount of venture capital
engaged in the early development stages of the life cycles of health care-related
products (Fleming, 2015).
Having in mind the current industrial organisation of innovation in health care,3
securing the finance at the very beginning of the innovation pathway in health care is
challenging and requires an in-depth understanding of investment strategies imple-
mented by venture capitalists. In turn, this creates an urgent need to take a broader
look at global trends in early-stage venture capital funding of health care-oriented
life-science projects.
This article aims to provide the outlook for early-stage venture capital investment
in Europe. There is a double rationale for it: first, most literature investigating this
topic focuses on the U.S.; second, we wish to test empirically whether data support
claims on the decline of financing for early-stage innovation efforts in life sciences
in Europe.
This article is organised as follows. The first section analyses the trends in V.C.-
backed funding of European companies operating within technology and life sciences
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related to health. It presents the related V.C. investment activities in the perspective
of last decade. In the subsequent section, we describe how European companies per-
form in attracting V.C. compared to other regions. Finally, we check whether invest-
ors’ decision towards allocation of funds have a short-term, speculative character, or
whether they are motivated by long-term expectations regarding the performance of
highly innovative companies within the health care sector. In the final section we pre-
sent concluding remarks and some policy recommendations, which are discussed in
the light of existing debates on the issue.
V.C. Dynamics: material and methods
We began our analysis by describing the relative position of the health care sector in
overall V.C. financing flows. This first comparison turned out to be the most difficult
one, since there are no standard international definitions of either venture capital or
venture capital by development stage. Moreover, the methodology of data collection
differs across countries and sectoral views vary across commercial data providers. In
order to partly overcome these difficulties, for international sectoral comparison, we
decided to explore the O.E.C.D. data (O.E.C.D. Entrepreneurship Financing Database).
The organisation collects and provides information on V.C. streams for Europe and
the U.S. for three industrial sectors, namely: I.C.T., Life sciences and Industrial/
Energy. Therefore, health care falls within Life Science category. By analysing the V.C.
data over the last decade, we may conclude that the venture capital investment gap
widened between the U.S. and Europe in all sectors. Moreover, in 2016, the
American I.C.T. sector received more than half of the total V.C. investments (53.6%),
followed by life sciences (20.7%). In Europe, the I.C.T. sector attracted almost 45% of
total V.C. funds (44% of the total), whereas life sciences sector received 27%. This
situation is depicted in Figure 1:
The O.E.C.D. sectoral analysis is supported by recent analyses from consulting
firms (P.W.C., 2018; KPMG, 2017). According to their findings, financing of pharma
and biotechnology sectors are booming in Europe; for the sole fourth quarter of
2017, companies from those sectors attracted more than US$300 million.
Figure 1. Venture Capital investments by sector (the U.S. versus Europe, US$ millions).
Source: Own calculation based on O.E.C.D. data.
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At this time, it is important to recall that V.C. dynamics were strongly affected by
the financial crisis of 2007–2009. Block, De Vries, and Sandner (2010) provide the
evidence of this adverse phenomena for a series of countries (Europe and the U.S.)
and across industries. In general, the global financial crisis led to a decrease in the
number of funding rounds, at first hitting funding more severely than in later rounds.
Additionally, the amount raised per funding round decreased, significantly impacting
sectors such as I.T./Internet and health care. However, the crisis did not have a sig-
nificant impact on the biotechnology sector.
As a further step, while exploring Thomson-Reuters E.I.K.O.N. platform, we
have identified the flows of early stage V.C. funding (seed and/or series A funds) to
European companies operating within health care industry. E.I.K.O.N. data include
a detailed tagging for all subsectors, and thus we had possibility to select all com-
panies having their main activity within life-science and technology with relation
to health care). The annual streams of investments since 2007 are depicted in
Figure 2:
In 2007, nearly US$300million was invested; the historical low was observed in
2009 with only US$138million allocated to European firms, which roughly constitutes
25% of funding in the record year of 2016. Since 2007, US$3.8 billion has been raised
in Europe. These funds have been split over 724 deals (Figure 3). While comparing
the annual dynamics, deal numbers were uneven, ranging from 49 in 2009 to 84 in
2016, with the mean deal value of US$5.5million.4
When controlling for subsectors in the health care industry, since 2008 there has
been a pronounced increase in the variety of health care businesses in the eye of
investors: at the beginning of the analysed period, investors were attracted only by
eight activities (led by DNA/RNA Probes), while in 2017, funding streams were dis-
persed across 44 subsectors. In Figure 4 we present the recent level of funding across
health care industry branches. The highest amounts were allocated to firms offering
Figure 2. Seed/Series A V.C. Flows to European companies operating within health care industry
(US$ millions, Q1 2007–Q3 2017).
Source: Authors’ compilation based on Thomson-Reuters data.
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biotechnology products, while companies supplying health services have attracted less
attention from investors (panel A). Moreover, the majority of deals were concluded
in less than five deals in most sectors, and this regardless of equity invested
(panel B). Finally, in most cases, up to 20 companies received financing in each sub-
sector (with an average number of 7, as depicted in panel C).
The accumulation of V.C. funds in health care subsectors since 2007 is presented
in Figure 5.
As depicted in Figure 5, in terms of value since 2007, companies developing med-
ical devices and equipment5 have received the most attention (US$49.48 billion), fol-
lowed by biotech firms (US$40.84 billion). In turn, companies focused on drug
development collected assets of US$24.58 billion.
In order to investigate simultaneously the structure of deals by investment stage
and value range, we have analysed the C.B. Insights data from 2009 to 2017. Fifty-
seven per cent of deals were provided as seed investment and the majority of these
vital fund injections had value of less than US$5million (Figure 6).
The geographical concentration of V.C. funding is clearly visible on the health care
industry heat-map (Figure 7).
Companies from North America, dominated by the U.S. since 2007, have received
more than a half of total funds, valued at US$500 billion.
Applying factor analysis on the global data on early stage V.C. financing in the
health care sector supports the leading position of the U.S. Specifically, since we have
information on deals (including the number of deals and their values), as well as on
location of investment destination (regional split), the factorisation procedure is pos-
sible. The resulting bi-dimensional performance of regions is presented in Figure 8,
where North America largely outperforms all remaining regions in terms of accumu-
lated equity and number of deals.6
Figure 3. Number of deals (Q1 2007–Q3 2017).
Source: Authors’ compilation based on Thomson-Reuters data.
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In Europe, U.K.-based companies attract the most of funding (US$74.7 billion),
followed by firms originated in Germany and France (Figure 9). There are only few
companies in Central and Eastern Europe backed by V.C.
Figure 4. Seed/Series A V.C. Flows to European companies by health care industry subsectors
(US$ millions, 2017).
Panel A: Average value of equity invested
Panel B: Number of deals
Panel C: number of firms
Source: Authors’ compilation based on Thomson-Reuters data
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The specific territorial attractiveness for V.C. funds can be attributable to the mar-
ket size and profitability conditions. More specifically, it is without surprise that the
U.S. takes the pole position: in this country, the intensity of V.C. capital measured as
a percentage of G.D.P. has been relatively stable over time, reaching 0.14 for early
stage investments and 0.22 for late fundraising in 2016 (OECD, 2017). The values of
Figure 4. Continued.
Figure 5. V.C. by health care subsector in Europe (value of investments, 2007–2017).
Source: Authors’ compilation based on C.B. Insights data.
Bricks are scaled to reflect the relative position of a subsector in attracting V.C. investments. Color shades reflect the
value of deals, while the bricks’ size represent the quantity of deals.
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Figure 6. Value of V.C. flows (deals and stages (Q1 2009–Q3 2017).
Source: Authors’ compilation based on C.B. Insights data.
Figure 7. Destination of V.C. flows in relation to health care (value of investments, Q1
2009–Q3 2017).
Source: Authors’ compilation based on C.B. Insights data.
Bricks are scaled to reflect the relative position of a country in attracting V.C. investments. Color shades reflect the
value of deals, while the bricks’ size represent the quantity of deals.
Figure 8. Factor analysis of V.C. flows in relation to health care.
Source: Authors’ own elaboration
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this indicator are more than halved for Europe: the European leader – the U.K. – in
2017 had the highest share of venture capital investments as a percentage of G.D.P.
of any European country at 0.08%. Only Sweden, France and Finland had a share of
venture capital as a percentage of G.D.P. that was also over 0.05% (Invest Europe,
2017). Moreover, if we consider the trends in earnings from capital investment in
health care industry, the U.S. and the U.K. display the highest rate of return from the
investments, especially in health care technology and medical equipment (annual
average E.B.I.T.D.A. were of 15–20% over the last decade in these countries).
However, the return on investment was dramatically low and uneven for biotech and
pharmaceutical subsectors: this finding supports the view that in pharmaceutical sub-
sectors earnings are particularly uncertain considering the length time for the prod-
ucts to enter the market (and to exit from the deals by V.C. investors). The poor
performance of the pharmaceutical sector in attracting V.C. can be mainly attributed
to the characteristics of regulatory environment. Clearly, when comparing review
times for new drugs approved by the U.S. Food and Drug Administration (F.D.A.)
and the European Medicines Agency, it appears that drugs were approved more
quickly in the U.S. with the median difference in approval time of 77 days (Downing,
Zhang, and Ross, 2017). Therefore, the American Agency moves faster, shortening
the regulatory cycle, thus making it more attractive for investors.
We have also identified the top 10 investors providing seed capital to European
companies within the health care sector (Table1). The benchmark is made upon the
value of seed capital allocated the over the period 2013–2017.
Among the most active seed fund providers we can observe the heterogeneity of
profiles. For instance, the leading investor in our sample (High-Tech Grunderfonds)
is Germany’s most active seed stage investor. The firm, however, does not focus solely
on health care firms. It also finances technology-driven companies operating in the
fields of robotics, cleantech or software. On the other hand, pharma moguls are seiz-
ing opportunities among young biotech companies with help of their corporate ven-
ture arms. This is precisely the case of Merc Ventures or Boehringer Ingelheim
Ventures; these entities invest wisely in firms whose innovativeness may speed-up the
R&D of their core activities. Their goal is also to create the spin-offs and thus lever-
age on synergies. Usually, these investors allocate the initial capital of up to US$2
Figure 9. Recipients of V.C. funds in Europe (in value, 2008–2017).
Source: Authors’ compilation based on C.B. Insights data.
Bricks are scaled to reflect the relative position of a country in attracting V.C. investments. Colour shades reflect the
value of deals, while the bricks’ size represent the quantity of deals.
ECONOMIC RESEARCH-EKONOMSKA ISTRAZIVANJA 9
million per venture, with subsequent staged investments made to align with each ven-
ture’s progress, up to a total of US$10–15 million per venture over its life.7 Finally,
we may notice the presence of public institutions, such as Banque Publique
d’Investissement (B.P.I. France), whose mission is to support small and medium
innovative enterprises in a wide array of sectors in France. The active participation of
public institutions supports the view of ‘patient capital’, that takes risks by providing
necessary capital injections to new entrepreneurial endeavours, and displays long-
term financial commitment to firms, and therefore lower risk of early divestments
(Lazonick and Mazzucato, 2013). Furthermore, Corporate Venture Capital starts to
play an important role in V.C. ecosystems as it creates the new source of capital for
financing health care innovation. According to the C.B. Insights data, C.V.C. activities
in the health care industry have reached an all-time record in 2017, which corre-
sponds to US$6.2 billion, with 218 deals, compared to 2016 when it reached US$4.9
billion with a total of 187 deals. It is also important to notice that the growing
Table 1. The most active V.C. fund providers in Europe.
Rank (value of capital provided) Investor
1 High-Tech Grunderfonds






8 Boehringer Ingelheim Ventures
9 Medixci Ventures
10 Nord West Fund for Bimedical
Source: Authors’ compilation based on C.B. Insights data.
Figure 10. European health care exits.
Source: Authors’ own elaboration based on C.B. Insights data.
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number of C.V.C.’s have engage at the seed stage (243 deals in 2017 compared to 168
deals in 2016); this implies that corporations are becoming aware of the importance
of having an ‘early seat’ on the value creation chain in innovative companies.
Finally, it is worth mentioning that the success of the venture capital fundraising is
dependent on earlier successful divestments. The exit opportunity is a key part of the
venture capital cycle and allows the quantitative assessments of venture capital firms’
performance (Schwienbacher 2008). As far as the health care industry is concerned,
by 2017, they accounted for 26% of overall global cross-industry divestments and
reached US$6.7 billion. Moreover, substantial differences between the U.S. and
Europe have been noticed. Divestment processes move faster in the U.S. than in
Europe, and differ mainly with respect to exit stage, the use of convertible securities,
the replacement of former management and deal syndication.
The exit strategies in European health care industry are presented in Figure 10.
Over the last decade, five subsectors have stood out from other subsectors by the
amount of funding and a number of divestments, namely: Medical Devices &
Equipment, Biotechnology, Medical Facilities & Services and Pharmaceuticals/Drugs.
Determinants of investment
In the literature, authors usually distinguish four main groups of factors that can pos-
sibly determine the V.C. investment. First, there are V.C. firm-related factors, such as
experience, specialization and reputation; Second, there are factors related to invest-
or’s portfolio preferences, such as industry, development stage or geographic proxim-
ity. Another group is composed of market factors, such as macroeconomic
environment and regulatory schemes. Finally, there are factors associated directly
with V.C. contracting and rights.
Independently of these factors, the logic of V.C. is the following one: capital providers
invest in a specific company only when the potential return on investment is sufficient
compared to the investment risk. Moreover, investing in early life cycle stage of a com-
pany is a risky endeavour, since the chances for a successful exit are low. Accordingly,
the V.C. investor requires more return from ‘young’ firms compared to mature compa-
nies. Reiner (2013) provides a comprehensive review of I.R.R. from V.C. investments
since the first empirical study on V.C. returns of Chiampou and Kallett (1989).
According to this long-term performance benchmark, the average I.R.R. of V.C. is 11.5%.
In this article, we take another direction: we relate the streams of quarterly ‘early’
V.C. financings in the European health care sector to the equity returns metric. The
idea is to check whether V.C. investors’ decisions are driven by the opportunities of
short-term profits or maybe they privilege long-term investment strategy eventually
leading to buyouts and spin-offs eliminating high risk levels in the short horizon.
In order to verify the above-mentioned hypothesis, we propose the following model:
lVCt ¼ ß0 þ ß1;tPEVCindext þ ß2;tPEVCindext1 þ et (1)
where lVCt denotes current stocks of V.C. investment (in logarithm) and PE_VC
measures current and past returns from investments8. In case investors have a long-
term strategy, we expect coefficients on equity return to be statistically insignificant.
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Using data from Thomson-Reuters E.I.K.O.N., we have compiled data sample with
quarterly V.C. investments (Q1 2007–Q2 2017) and added quarterly information on
returns from V.C. financing provided by Cambridge Associates. This metric is a com-
posite performance index9 frequently used for benchmarking P.E./V.C. performance.
It is important to notice, the levels of returns are characterised by substantial variance
and display high volatility over time, as depicted in Figure 11.
Since we have confirmed a stationarity of time series, the consistent ordinary least
squares estimates of (1) are presented in Table 2.
The coefficient on return displays a limited significance and also rather
unattended, negative sign. It might be the case that V.C. investors pay attention to
short-term benefits but, at the same time, they remain sensitive to the cyclical nature
of returns and therefore, their decisions are based on internalising the ex post risks.
Conclusion
In the light of our analysis, it is difficult to detect a clear pattern in early stage V.C.
financings of European companies within the health care sector. Since 2007, the flows









Standard errors in parentheses.indicates significance at the 10% level.indicates significance at the 5% level.
Figure 11. Quarterly returns on P.E./V.C. and its volatility (in %).
Source: Authors’ elaboration based on Cambridge Associates data.
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have been uneven, characterised by high volatility. Moreover, the number of deals
varies greatly over time. Companies that managed to raise the most of capital are
located in the U.K., Germany and France. Sadly, there are only few firms that succeed
in raising V.C. in Central and Eastern Europe. At the same time, the low levels of
V.C. invested in Europe can be partly explained by the high volatility and thus uncer-
tainty of returns. It must be remembered, however, that health care industry returns
in long-term perspective, outperformed all remaining sectors, including financials and
consumer goods (both P.E. favourites). From this perspective, scepticism of V.C. to
invest in the health care sector remains much of a puzzle.
In terms of both value and deals, Europe is lagging behind the funding levels of
the U.S.
In policy language, this means that Europe can miss the opportunities of biotech-
nology and pharma revolution and may not be able to positively impact people’s
health. Clearly, in the situation of insufficient private financing, Europe should
increase the level of public financial support to help promising companies innovate.
The fuelling of the innovation pipeline should include, among others: supporting
small companies with necessary financing for early-stage periods (and thus substitute
the missing venture-capital streams), lowering regulatory uncertainties by creating
fast Health Technology Assessment mechanism and providing financial support for
expensive clinical trials. Already, some positive signs are visible. European Union,
through grants and other financial schemes, is allocating substantial resources to proj-
ects of high societal value, especially in the area of public health. Many small compa-
nies providing innovative technologies in genomics or big data are being injected
with necessary funds, and frequently participate in advancing science within health
care-oriented alliances or public–private partnerships.
Notes
1. In the health care industry, it takes, on average, 12 years from conception to market
lunch, compared to five years in automotive industry and seven in commercial aircraft
manufacturing; the development of a new drug requires on average US$2.6 billion
(Deloitte, 2014).
2. Firms operating within the health care sector spend the highest proportion of their
revenue on R&D compared to other technology-intense sectors (Janssen Health Policy
Center, 2015).
3. Literature acknowledges the rise of cooperative activities within health care industry,
starting with R&D alliances or joint-ventures in biotechnology and pharma sectors, up to
creation or extending the markets for innovative medical devices, procedures or services.
In the end, innovative activities, from being 100% in-house, have shifted towards a
heterogeneity of organisational form based on pooled resources, combining efforts of
industry moguls and specialised start-ups. A comprehensive study on this topic can be
found in Baker, Gibbons, & Murphy (2008) and Lazonick and Tulum (2011).
4. Median value is US$4.25 million.
5. The Medical devices and equipment category embraces surgical devices, imaging and
diagnostic equipment, therapeutic devices, and patient monitoring.
6. Factor 1 (component 1) is built on the following variables: number and value of deals
and number of companies that received V.C. investment; factor 2 (component 2)
represent the total value of equity invested.
7. This supports the recent findings of Lehoux et. al. (2016)
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8. The choice of log-level model has been confirmed by histograms. Lags have been
determined with autocorrelation matrix.
9. P.E./V.C. Impact Investing Fund SizeUS$100 million: Fund Index Details: One Quarter
Horizon Pooled Return. This index is ‘a horizon calculation based on data compiled
from 43 private equity and venture capital funds, including fully liquidated partnerships,
formed between 1998 and 2014. All returns are net of fees, expenses, and carried interest.
Historic quarterly returns are updated in each year-end report to adjust for changes in
the index sample’ (Cambridge Associates 2017: PE/VC Impact Investing Index &
Benchmark Statistics, available at: https://www.cambridgeassociates.com/benchmarks/
accessed 20 November 2017).
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